EQS-News

SCHOTT Pharma appoints Tobias Erfurth as Head of Investor Relations

EQS-News: SCHOTT Pharma AG & Co. KGaA / Key word(s): Personnel SCHOTT Pharma appoints Tobias Erfurth as Head of Investor Relations 30.04.2024 / 17:00 CET/CEST The issuer is solely responsible for the content of this announcement. SCHOTT Pharma appoints Tobias Erfurth as Head of Investor Relations

• Tobias Erfurth will lead Investor Relations Team starting in August 2024.
• He brings more than 20 years of experience in finance, capital markets and investor relations.

SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, today announced the appointment of Tobias Erfurth as Head of Investor Relations effective August 2024. He will strengthen and expand the Investor Relations team at SCHOTT Pharma and will report to CFO Almuth Steinkühler. “Tobias joining our finance team is a real win for SCHOTT Pharma. With his extensive expertise and DAX40 experience, we look forward to further growing SCHOTT Pharma’s presence in the capital markets and showcasing our attractive financial profile,” said Dr. Almuth Steinkühler, CFO of SCHOTT Pharma.

Tobias Erfurth has gained more than 20 years of experience in finance, capital markets and investor relations, both from corporate positions and roles in banking. In his most recent position as Head of Investor Relations at Symrise AG for over 13 years, Erfurth was responsible for managing all investor activities during the company’s development from a small cap to a member of the DAX40. Prior to that, Erfurth accompanied the IPO of Crop Energies AG and subsequently built up the investor relations department. Erfurth also has extensive experience in corporate finance and equity capital markets gained in his previous role as analyst at Dresdner Bank.

“With its convincing equity story, dynamic growth, attractive margins, SCHOTT Pharma is a true success story, and I look forward to joining the team. Together, we will continue to deepen the established relationships with investors and analysts and help key stakeholders to understand SCHOTT Pharma’s strategy and its role as a pioneer in one of the fastest growing markets of the pharma industry,” said Tobias Erfurth.